Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain.

Article Details

Citation

Witenko C, Moorman-Li R, Motycka C, Duane K, Hincapie-Castillo J, Leonard P, Valaer C

Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain.

P T. 2014 Jun;39(6):427-35.

PubMed ID
25050056 [ View in PubMed
]
Abstract

For patients with low back pain, skeletal muscle relaxants are often initiated after failure of first-line analgesics. However, these medications (reviewed in this article) are controversial alternatives that carry risks of adverse effects and increased cost.

DrugBank Data that Cites this Article

Drugs
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
CyclobenzaprineCytochrome P450 3A4ProteinHumans
Unknown
Substrate
Details
Drug Interactions
DrugsInteraction
Orphenadrine
Botulinum toxin type B
Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Orphenadrine
Tryptophan
Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Orphenadrine
Fluvoxamine
Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Orphenadrine
Lorazepam
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Orphenadrine
Ethchlorvynol
Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.